Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients

Table 3 Comparison of characteristics of 41 patients on the basis of antibody-dependent cell-mediated cytotoxicity activity

	ADCC < 71%	n = 20	ADCC > 71%	n = 21	P
Gender
Male (M)	11	55%	12	57%	0.91
Female (F)	9	45%	9	43%
Primary tumour
Right colon	5	25%	2	10%	0.282
Left colon	8	40%	13	62%
Rectal	7	35%	6	29%
Grade
G1/G2	13	65%	14	67%	0.872
G3	7	35%	6	29%
NA	0	0%	1	5%
Metastasis
Liver only and liver plus other sites	12	60%	14	67%	0.651
Extra-hepatic sites	8	40%	7	33%
Response
Responders
CR	3	15%	1	5%	0.362
PR	4	20%	8	38%
SD	3	15%	5	24%
Non-responders
PD	10	50%	7	33%
Line of treatment
II	17	85%	17	81%	12
III	3	15%	4	19%
EGFR
Neg; 1+; 2+	19	95%	14	67%	0.0522
3+	1	5%	5	24%
NA	0	0%	2	10%

¹Pearson’s Test;

²Fisher’s Exact Test; NA: Not available; Neg: Negative; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ADCC: Antibody-dependent cell-mediated cytotoxicity; EGFR: Epidermal growth factor receptor.